Literature DB >> 27698847

Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.

Edvina Galié1, Rosaria Renna2, Domenico Plantone1, Andrea Pace1, Mirella Marino3, Bruno Jandolo1, Tatiana Koudriavtseva1.   

Abstract

Morvan's syndrome (MoS) is a rare, complex neurological disorder characterized by neuromyotonia, neuropsychiatric features, dysautonomia and neuropathic pain. The majority of MoS cases have a paraneoplastic aetiology, usually occurring prior to the diagnosis of the underlying tumour and showing improvement following its treatment. The present study reports the case of a 35-year-old Caucasian male patient who was diagnosed with stage IVA thymoma. Thymectomy, lung resection, diaphragmatic pleurectomy and pericardio-phrenectomy were performed 6 months after neoadjuvant chemotherapy. The pathological evaluation revealed a type B2-B3 thymoma with focal squamous differentiation. Two years later, the patient underwent new surgical treatment for a local recurrence of the same histological type, and 4 weeks later, the patient presented with complex neurological symptoms compatible with MoS, including neuromyotonia, neuropsychiatric features, dysautonomia and neuropathic pain. Electromyography was compatible with a diagnosis of neuromyotonia. Brain magnetic resonance imaging scan and tests for serum anti-acetylcholine receptor, anti-striated muscle antibodies and anti-30-kDa titin fragment antibodies were all negative, whereas tests for anti-voltage-gated potassium channel (VGKC)-complex antibodies (333.3 pmol/l), anti-leucine-rich glioma inactivated protein 1 and anti-contactin-associated protein-like 2 antibodies were positive. The patient underwent 3 cycles of intravenous administration of immunoglobulins (0.4 g/kg/day for 5 days every 4 weeks) with little clinical and electrophysiological improvement. We speculated that the late onset of the symptoms in the present patient may have been triggered by an increase in the serum level of anti-VGKC antibody, which was caused by the surgery performed for the treatment of recurrent thymoma. To the best of our knowledge, the present report is the first case of MoS associated with this histological type of thymoma uncommonly occurring upon surgical treatment of recurrent thymoma.

Entities:  

Keywords:  Morvan's syndrome; contactin-associated protein-2; glioma inactivated 1; leucine-rich; thymic carcinoma; thymoma; voltage-gated potassium channel-complex antibodies

Year:  2016        PMID: 27698847      PMCID: PMC5038355          DOI: 10.3892/ol.2016.4922

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome.

Authors:  Chloé Laurencin; Nathalie André-Obadia; Jean-Philippe Camdessanché; François Mauguière; Elodie Ong; Sandra Vukusic; Laure Peter-Derex; David Meyronet; Françoise Bouhour; Christophe Vial; François Ducray; Jérôme Honnorat; Philippe Petiot
Journal:  Neurology       Date:  2015-09-23       Impact factor: 9.910

2.  Morvan syndrome: after scrotal sac drainage and chemical instillation in hydrocele.

Authors:  Sanjay Sharma; Pranita Sharma
Journal:  Neurol India       Date:  2013 May-Jun       Impact factor: 2.117

3.  Immunotherapy of oneiric stupor in Morvan syndrome: Efficacy documented by actigraphy.

Authors:  Simone Baiardi; Federica Provini; Patrizia Avoni; Marco Pasquinelli; Rocco Liguori
Journal:  Neurology       Date:  2015-05-15       Impact factor: 9.910

4.  Post-therapy normalization of brain FDG-PET in Morvan's syndrome.

Authors:  L Benedetti; D Franciotta; M Zoccarato; A Beronio; M Godani; E Schirinzi; G Siciliano; A Ciarmiello; M Del Sette
Journal:  J Neurol Sci       Date:  2015-04-01       Impact factor: 3.181

5.  Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels.

Authors:  S Poliak; L Gollan; R Martinez; A Custer; S Einheber; J L Salzer; J S Trimmer; P Shrager; E Peles
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

6.  [Sleep disturbances in a case of Morvan's chorea (author's transl)].

Authors:  L Murri; U Bonuccelli; A Iudice; C Simonetti
Journal:  Riv Patol Nerv Ment       Date:  1976 Nov-Dec

7.  Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex.

Authors:  Panayiotis Loukaides; Natasa Schiza; Philippa Pettingill; Lakis Palazis; Emmelia Vounou; Angela Vincent; Kleopas A Kleopa
Journal:  J Neurol Sci       Date:  2011-09-08       Impact factor: 3.181

8.  Morvan Syndrome: A Case Report With Patient Narrative and Video.

Authors:  Mark Maskery; Suresh K Chhetri; Rejith Dayanandan; Claire Gall; Hedley C A Emsley
Journal:  Neurohospitalist       Date:  2016-01

Review 9.  Thymoma associated with autoimmune diseases: 85 cases and literature review.

Authors:  C Bernard; H Frih; F Pasquet; S Kerever; Y Jamilloux; F Tronc; B Guibert; S Isaac; M Devouassoux; L Chalabreysse; C Broussolle; P Petiot; N Girard; P Sève
Journal:  Autoimmun Rev       Date:  2015-09-25       Impact factor: 9.754

Review 10.  LGI proteins in the nervous system.

Authors:  Linde Kegel; Eerik Aunin; Dies Meijer; John R Bermingham
Journal:  ASN Neuro       Date:  2013-06-25       Impact factor: 4.146

View more
  2 in total

Review 1.  Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes.

Authors:  Cheran Elangovan; Adeolu Morawo; Aiesha Ahmed
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.972

2.  Extrapleural pneumonectomy for recurrent thymoma diagnosed after return of paraneoplastic Morvan syndrome.

Authors:  Kian C Banks; Diana S Hsu; Jeffrey B Velotta
Journal:  J Surg Case Rep       Date:  2022-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.